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SRadiofrequency ablation for nondysplastic Barrett’s esophagus:
Should we do it, because we can?Nirmal Veeramachaneni, MDThe treatment of patients with Barrett’s esophagus has
been a topic of intense investigation for the last several de-
cades. Although it is well recognized that Barrett’s esopha-
gus may develop into dysplasia and then progress to
invasive esophageal cancer, initial studies comparing fun-
doplication surgery and the best medical management avail-
able demonstrated no difference in either regression of the
Barrett’s esophagus or diminution of cancer risk.1 More
modern randomized, controlled trials that investigated lap-
aroscopic fundoplication or long-term proton pump inhibi-
tor use also did not demonstrate any regression of Barrett’s
esophagus with either strategy2 after 5 years of follow-up.
In fact, the American Gastroenterological Association
does not currently recommend routine surgery (fundoplica-
tion) to treat Barrett’s esophagus.3 Strategies to eradicate
Barrett’s esophagus by means of radiofrequency ablation
in patients with high-grade dysplasia, however, havedemonstrated efficacy in preventing the progression to
esophageal cancer.4
In the accompanying article in this issue of the Journal,
Korst and colleagues5 have extended the application of ra-
diofrequency ablation technology in a phase 2 trial of pa-
tients with Barrett’s esophagus without evidence of
dysplasia (72% of patients enrolled). This study demon-
strated efficacy in eradicating Barrett’s esophagus in 78%
of treated patients. Patients with large hiatal hernias were
found to be at risk for impaired healing of the esophageal
lining after radiofrequency ablation. This study provides
valuable information on the intensity of follow-up and treat-
ment necessary to treat Barrett’s esophagus with radio-
frequency ablation technology. There is considerable
variation with respect to the number of radiofrequency ab-
lation treatments needed, with as many as 5 treatments
needed for patients with less than 2 cm Barrett’s esophagus
and as many as 8 treatments needed for patients with greater
than 5 cm of Barrett’s esophagus. Treatments were done at
2-month intervals. Although the study patients have under-
gone careful endoscopic follow-up, the long-term efficacy
of the strategy remains unclear. Korst and colleagues5 are
unable to provide long-term follow-up data, and the rate
of recurrent Barrett’s esophagus is unknown. In addition,
there is no assessment for potential buried islands of Bar-
rett’s esophagus. Furthermore, given the low rate of pro-
gression of nondysplastic Barrett’s esophagus to cancer,
the utility of the intervention, even if successful, is unclear.diovascular Surgery c Volume 142, Number 5 1173
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Commentary VeeramachaneniRoutine endoscopic screening for Barrett’s esophagus in
the general population is currently not recommended.3 For
patients with Barrett’s esophagus without dysplasia, follow-
up surveillance endoscopy is only recommended every 3 to
5 years, in recognition of the relatively low risk of progres-
sion to more advanced dysplasia. More intense surveillance
and possibly surgical resection or ablation is recommended
if more advanced dysplasia is discovered.
In light of the ambiguity of the natural history of Bar-
rett’s esophagus without dysplasia, radiofrequency abla-
tion should currently only be done in the context of
a clinical trial. Although this article by Korst and col-
leagues5 brings up intriguing possibilities, routine radio-
frequency ablation for nondysplastic Barrett’s esophagus
should not be considered the standard of care. Further
work allowing risk stratification of subjects at increased
likelihood for progression to high-grade dysplasia and1174 The Journal of Thoracic and Cardiovascular Surcancer will be necessary for better targeting of this inter-
vention in low-risk populations.References
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